A Phase III study of SIM0237
Latest Information Update: 13 Apr 2026
At a glance
- Drugs SIM-0237 (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
Most Recent Events
- 13 Apr 2026 New trial record
- 17 Mar 2026 According to Jiangsu Simcere Pharmaceutical Media Release, based on result data from phase I/II study company plans advancing Phase III studies.